Four-Year Subset Analysis from Global ENGAGE Registry Demonstrates Positive Outcomes in Challenging Anatomies DUBLIN and NEW YORK CITY- November 17, 2015 - Selected for nearly one of every two ...

New Data from the Global ENGAGE Registry Builds on Durability of Endurant, with Strong Outcomes Out to Four Years in Patients with Standard and Hostile Neck Anatomies Created with the collaboration of ...

Enhanced Medical Device to Repair Abdominal Aortic Aneurysms Without Open Surgery Expands Physicians’ Options for Treating ‘Silent Killer’ MINNEAPOLIS –– Medtronic Inc. today announced the CE ...

Medtronic plcMDT, a leading player in the medical device and technology space, recently won CE mark for its Endurant II/IIs stent graft system to treat abdominal aortic aneurysm (AAA) patients through ...

Leading the development of endovascular aortic repair (EVAR), Medtronic, Inc. (NYSE: MDT) today announced the start of its U.S. post-approval study of the Endurant ® AAA Stent Graft System, a medical ...

Leading medical devices player, Medtronic (NYSE:MDT - News) announced the receipt of CE Mark followed by the launch of Endurant II AAA stent graft system in the international market. The launch of ...

New Bifurcated Component Leverages Proven Design of Predicate Device and Expands Anatomical Customization Options for Endovascular Repair of Abdominal Aortic Aneurysms The new device joins the ...

Medtronic is First and Only Company to Receive Approval for a ChEVAR Indication, Providing an Off-the-Shelf Option for Patients with Complex Aneurysms DUBLIN - Dec. 6, 2016 - Medtronic plc (NYSE:MDT) ...

Medtronic Inc. (NYSE: MDT) today announced the CE (Conformité Européenne) mark and international launch of the Endurant ® II AAA Stent Graft System, which meaningfully expands the options physicians ...

Leading medical devices player, Medtronic ( MDT) announced the receipt of CE Mark followed by the launch of Endurant II AAA stent graft system in the international market. The launch of this device ...